샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941542

전임상 이미징 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Preclinical Imaging Market Size, Share & Trends Analysis Report By Type, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전임상 이미징 시장 요약

세계의 전임상 이미징 시장 규모는 2025년에 10억 5,000만 달러로 평가되었으며, 2033년까지 16억 3,000만 달러에 달할 것으로 예측됩니다.

2026년부터 2033년까지 5.6%의 CAGR을 보일 것으로 예상됩니다. 이러한 성장은 만성질환 유병률 증가, 의약품 개발에 대한 투자 증가, 비침습적 영상기술에 대한 수요 증가에 의해 주도되고 있습니다.

초기 단계의 연구에서 첨단 이미징 기법의 도입과 번역 연구(translational research)의 확대와 함께 시장 확대가 더욱 가속화되고 있습니다.

미국 국립보건원(NIH)과 유럽 및 아시아의 유사 기관들의 보조금 및 자금 지원을 포함한 정부 주도의 노력은 전임상 연구를 크게 강화하여 전임상 이미징 시장을 뒷받침하고 있습니다. 예를 들어, 2022년 9월 NIH와 미국 보건사회복지부(DHHS)는 장독소 생성 대장균(ETEC), 파라티푸스균 A형, 이질균을 표적으로 하는 마일스톤형 전임상 백신 개발 공모를 진행했습니다.

이 프로그램은 백신 최적화, 스케일업, 안전성 및 유효성 시험을 지원하고, 후보 백신이 임상시험 준비 단계에 도달할 수 있도록 5년간 연간 최대 75만 달러를 지원했습니다. 신청 자격은 학술기관, 비영리단체, 정부기관, 기업 등이 대상이었습니다. 국립알레르기-전염병연구소(NIAID)는 후보 백신의 FDA 임상시험 신청(IND)을 위한 진전을 촉진하기 위해 4-6개 프로젝트에 총 520만 달러를 지원할 예정입니다. 이번 자금 유입으로 연구자들은 첨단 플랫폼에 대한 투자, 신규 프로브 개발, 종단 연구 확대, 전임상 생체 내 이미징 시장의 수요 증가 및 광학 전임상 이미징 등의 분야 성장을 지원할 수 있게 되었습니다.

자주 묻는 질문

  • 전임상 이미징 시장 규모는 어떻게 변할 것으로 예상되나요?
  • 전임상 이미징 시장의 성장은 어떤 요인에 의해 주도되고 있나요?
  • 정부의 지원은 전임상 이미징 시장에 어떤 영향을 미치고 있나요?
  • NIH의 전임상 백신 개발 공모에 대한 지원 내용은 무엇인가요?
  • 전임상 생체 내 이미징 시장의 수요 증가에 대한 지원은 어떻게 이루어지고 있나요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전임상 이미징 시장 변수, 동향 및 범위

제4장 전임상 이미징 시장 : 유형별 추정·동향 분석

제5장 전임상 이미징 시장 : 용도별 추정·동향 분석

제6장 전임상 이미징 시장 : 최종 용도별 추정·동향 분석

제7장 전임상 이미징 시장 : 지역별 추정·동향 분석(유형별, 용도별, 최종 용도별)

제8장 경쟁 구도

KSM

Preclinical Imaging Market Summary

The global preclinical imaging market size was valued at USD 1.05 billion in 2025 and is expected to reach USD 1.63 billion by 2033, growing at a CAGR of 5.6% from 2026 to 2033. This growth is driven by the rising prevalence of chronic diseases, increasing investments in drug development, and growing demand for non-invasive imaging techniques.

The adoption of advanced imaging modalities for early-stage research, coupled with the expansion of translational research initiatives, further accelerates market expansion.

Government initiatives, including grants and funding from organizations such as the National Institutes of Health (NIH) and similar agencies in Europe and Asia, are significantly enhancing preclinical research and bolstering the preclinical imaging market. For example, in September 2022, the NIH and the U.S. Department of Health and Human Services (DHHS) called for applications for milestone-driven preclinical vaccine development targeting Enterotoxigenic Escherichia coli (ETEC), Salmonella Paratyphi A, and Shigella species.

The program supported vaccine optimization, scale-up, safety, and efficacy testing, offering up to USD 750,000 annually over five years to help candidates reach clinical readiness. Eligible applicants included academic institutions, nonprofits, governments, and businesses. The National Institute of Allergy and Infectious Diseases (NIAID) planned to award USD 5.2 million across 4-6 projects to advance candidates toward FDA IND submission. This influx of funding allows researchers to invest in advanced platforms, develop new probes, and expand longitudinal studies, increasing demand in the preclinical in-vivo imaging market and supporting growth in segments like optical preclinical imaging.

Global Preclinical Imaging Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preclinical imaging market based on type, application, end use and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Modality
    • Optical Imaging (BLI & F)
    • Magnetic Resonance Imaging (MRI)
    • Positron Emission Tomography (PET)
    • Single Photon Emission Computed Tomography (SPECT)
    • Computed Tomography (CT)
    • Ultrasound Imaging (US)
    • Photoacoustic Imaging (PAI)
    • Hybrid Imaging Systems
    • Bi-Modal
    • SPECT-CT
    • PET-CT
    • SPECT-PET
    • PET-MRI
    • Optical-CT
    • Others
    • Tri-Modal
    • PET-SPECT-CT
    • PET-SPECT-MRI
    • PET-CT-Optical
    • Others
    • Others
  • Reagent
  • Service
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery & Development
  • Toxicology & Pharmacokinetics Studies
  • Basic & Translational Research
  • Disease Mechanism & Pathophysiology Studies
    • Oncology
    • Cardiology
    • Neurology
    • Infectious Diseases
    • Immunology & Inflammation
    • Others
  • Biomarker & Imaging Agent Validation
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma and Biotech Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Preclinical Imaging Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Preclinical Imaging Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Preclinical Imaging Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Preclinical Imaging Type Market Movement Analysis
  • 4.3. Global Preclinical Imaging Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Modality
    • 4.4.1. Modality market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Optical Imaging (BLI & F)
      • 4.4.2.1. Optical Imaging (BLI & F) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Magnetic Resonance Imaging (MRI)
      • 4.4.3.1. Magnetic Resonance Imaging (MRI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Positron Emission Tomography (PET)
      • 4.4.4.1. Positron Emission Tomography (PET) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Single Photon Emission Computed Tomography (SPECT)
      • 4.4.5.1. Single Photon Emission Computed Tomography (SPECT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Computed Tomography (CT)
      • 4.4.6.1. Computed Tomography (CT) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Ultrasound Imaging (US)
      • 4.4.7.1. Ultrasound Imaging (US) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. Photoacoustic Imaging (PAI)
      • 4.4.8.1. Photoacoustic Imaging (PAI) market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Hybrid Imaging Systems
      • 4.4.9.1. Hybrid Imaging Systems market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.2. Bi-Modal
        • 4.4.9.2.1. Bi-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.2. SPECT-CT
          • 4.4.9.2.2.1. SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.3. PET-CT
          • 4.4.9.2.3.1. PET-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.4. SPECT-PET
          • 4.4.9.2.4.1. SPECT-PET market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.5. PET-MRI
          • 4.4.9.2.5.1. PET-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.6. Optical-CT
          • 4.4.9.2.6.1. Optical-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.2.7. Others
          • 4.4.9.2.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.9.3. Tri-Modal
        • 4.4.9.3.1. Tri-Modal market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.2. PET-SPECT-CT
          • 4.4.9.3.2.1. PET-SPECT-CT market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.3. PET-SPECT-MRI
          • 4.4.9.3.3.1. PET-SPECT-MRI market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.4. PET-CT-Optical
          • 4.4.9.3.4.1. PET-CT-Optical market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.9.3.5. Others
          • 4.4.9.3.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.10. Others
      • 4.4.10.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Reagent
    • 4.5.1. Reagent market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Service
    • 4.6.1. Service market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Preclinical Imaging Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Preclinical Imaging Application Market Movement Analysis
  • 5.3. Global Preclinical Imaging Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 5.4. Drug Discovery & Development
    • 5.4.1. Drug Discovery & Development market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Toxicology & Pharmacokinetics Studies
    • 5.5.1. Toxicology & Pharmacokinetics Studies market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Basic & Translational Research
    • 5.6.1. Basic & Translational Research market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Disease Mechanism & Pathophysiology Studies
    • 5.7.1. Disease Mechanism & Pathophysiology Studies market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.2. Oncology
      • 5.7.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.3. Cardiology
      • 5.7.3.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.4. Neurology
      • 5.7.4.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.5. Infectious Diseases
      • 5.7.5.1. Infectious Diseases market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.6. Immunology & Inflammation
      • 5.7.6.1. Immunology & Inflammation market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.7.7. Others
      • 5.7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. Biomarker & Imaging Agent Validation
    • 5.8.1. Biomarker & Imaging Agent Validation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Preclinical Imaging Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Preclinical Imaging End Use Market Movement Analysis
  • 6.3. Global Preclinical Imaging Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Pharma and Biotech Companies
    • 6.4.1. Pharma and biotech companies market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Contract Research Organizations (CROs)
    • 6.5.1. Contract Research Organizations (CROs) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Academic and Research Institutes
    • 6.6.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Preclinical Imaging Market: Regional Estimates & Trend Analysis By Type, Application, End Use

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement structure
      • 7.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement structure
      • 7.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement structure
      • 7.5.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement structure
      • 7.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement structure
      • 7.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement structure
      • 7.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement structure
      • 7.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement structure
      • 7.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement structure
      • 7.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement structure
      • 7.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Reimbursement structure
      • 7.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement structure
      • 7.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement structure
      • 7.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement structure
      • 7.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement structure
      • 7.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement structure
      • 7.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement structure
      • 7.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement structure
      • 7.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement structure
      • 7.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement structure
      • 7.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement structure
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Reimbursement structure
      • 7.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Reimbursement structure
      • 7.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2025
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders)
  • 8.6. Company Profiles
    • 8.6.1. Cubresa Inc.
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. Bruker Corporation
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. Revvity (PerkinElmer, Inc)
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. FUJIFILM VisualSonics
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Mediso Ltd.
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Rigaku (MILabs B.V.)
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. MR Solutions
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. Aspect Imaging
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. TriFoil Imaging
      • 8.6.9.1. Company overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Strategic initiatives
    • 8.6.10. Siemens Healthineers
      • 8.6.10.1. Company overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제